Systemic Administration of siRNA With Anti-Hb-Egf Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer

doi 10.1021/acs.molpharmaceut.7b01055.s001
Full Text
Abstract

Available in full text

Date

Unknown

Authors

Unknown

Publisher

American Chemical Society (ACS)

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy